PTC Therapeutics reported $161.9M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
Daiichi Sankyo JPY 116.06B 14.46B Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026